Analyzing Orchestra BioMed (NASDAQ:OBIO) and Enovis (NYSE:ENOV)

Enovis (NYSE:ENOV) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Enovis and Orchestra BioMed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1	1	10	0	2.75
Orchestra BioMed	1	0	7	0	2.75

Enovis currently has a consensus target price of $40.38, suggesting a potential upside of 123.94%. Orchestra BioMed has a consensus target price of $13.17, suggesting a potential upside of 116.56%. Given Enovis’ higher possible upside, research analysts plainly believe Enovis is more favorable than Orchestra BioMed.

Insider and Institutional Ownership

98.5% of Enovis shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 2.9% of Enovis shares are owned by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Enovis and Orchestra BioMed”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25 billion	0.46	-$1.18 billion	($19.26)	-0.94
Orchestra BioMed	$33.48 million	10.91	-$52.70 million	($0.85)	-7.15

Orchestra BioMed has lower revenue, but higher earnings than Enovis. Orchestra BioMed is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Enovis has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.

Profitability

This table compares Enovis and Orchestra BioMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enovis	-47.96%	12.03%	4.91%
Orchestra BioMed	-184.60%	-149.61%	-54.15%

Summary

Enovis beats Orchestra BioMed on 9 of the 13 factors compared between the two stocks.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.